LRRK2 and Parkinson disease: Notably, LRRK2 kinase inhibition reversed mtDNA damage in iPD patient-derived lymphoblastoid cells, suggesting LRRK2 kinase activity contributes to mtDNA damage in PD patients without a pathogenic LRRK2 mutation [107].